Sakar Healthcare Limited (SAKAR) — Financial Results Announcement
Investor Takeaways
Overall Tone: Positive
Key Financial Highlights
| Metric | Value | YoY Change |
|---|---|---|
| Revenue | ₹7126.82 Cr | N/A |
| Net Profit | ₹1102.43 Cr | N/A |
| EPS | ₹4.96 | N/A |
| OPM | Not available | N/A |
What Changed
Sakar Healthcare Limited released its audited consolidated financial results for FY2026 on May 12, 2026, reporting revenue of ₹7126.82 crores and profit after tax of ₹1102.43 crores. The filing confirms stable financial operations with no material changes or forward-looking projections disclosed. The company maintains a stable financial position, supported by an unmodified auditor's opinion and compliance with Ind AS and listing regulations. Earnings per share for the year were recorded at ₹4.96. The results reflect consistent performance across reporting periods, with quarterly revenue and profit figures showing incremental growth over the last four quarters. The company does not appear to be disclosing any strategic shifts or capital allocation plans in this filing.
Peer Comparison
| Company | P/E | ROE | ROCE | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Sakar Healthcare Limited | 102.31 | Not available | Not available | 1,550.15 |
| Sun Pharmaceutical Industries Limited | 41.28 | 15.11% | 20.34% | 4,50,643.09 |
| Divi's Laboratories Limited | 72.41 | 16.56% | 22.09% | 1,79,470.03 |
| Torrent Pharmaceuticals Limited | 80.06 | N/A | N/A | 1,49,108.91 |
Sakar Healthcare is trading at a significantly higher P/E multiple compared to Sun Pharmaceutical and Divi's Laboratories, suggesting market expectations may be priced at a premium. However, its market capitalization is considerably lower than that of its large-cap peers, indicating a smaller scale of operations.
Risks & Concerns
Quarterly Trend
| Quarter | Revenue (₹ Cr) | Net Profit (₹ Cr) | OPM% |
|---|---|---|---|
| Q3FY25 | 43.42 | 4.53 | 27.08 |
| Q2FY25 | 42.78 | 4.8 | 26.88 |
| Q1FY25 | 41.15 | 2.41 | 26.03 |
| Q4FY24 | 43.06 | 3.12 | 25.5 |
The quarterly trend shows fluctuating profitability, with peak profit after tax observed in Q2FY25 at ₹4.8 crores and lowest in Q1FY25 at ₹2.41 crores. Revenue remained relatively stable across quarters, ranging between ₹41.15 crores and ₹43.42 crores. OPM declined slightly over the period, from 27.08% in Q3FY25 to 25.5% in Q4FY24. EPS followed a similar pattern, peaking at ₹2.17 in Q2FY25 and dropping to ₹1.10 in Q1FY25. These figures indicate variability in quarterly performance, though no significant upward or downward trend is evident in the short term. The annual FY2026 results, however, reflect a substantial increase in revenue and profitability compared to these quarterly figures, suggesting possible scale effects or one-time contributions not captured in the quarterly data provided.
📄 View Original Announcement (PDF)
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.